Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.
about
Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog TherapyKASL clinical practice guidelines: management of chronic hepatitis BMetabonomic window into hepatitis B virus-related hepatic diseasesRecent advances in understanding and diagnosing hepatitis B virus infectionAsian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Current hepatitis B treatment guidelines and future research directions.Chronic hepatitis B: Advances in treatment.Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients.Baseline value of intrahepatic HBV DNA over cccDNA predicts patient's response to interferon therapyQuantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon.Is it more cost-effective for patients with chronic hepatitis b to have a trial of interferon before considering Nucleos(t)ide analogue therapy?Hepatitis B virus genotypes and variants.Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis.Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.AIC649 Induces a Bi-Phasic Treatment Response in the Woodchuck Model of Chronic Hepatitis B.Correlations of IFN-γ-inducible protein-10 with the risk of chronic hepatitis B and the efficacy of interferon therapy in Asians.Elimination of Hepatitis B: Is It a Mission Possible?CD3(bright)CD56(+) T cells associate with pegylated interferon-alpha treatment nonresponse in chronic hepatitis B patients.Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2aVirus and Host Testing to Manage Chronic Hepatitis B.Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysisCONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients: A prospective, randomized study.An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys): TRACES StudyOn-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis BKinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment.A rationalized approach to the treatment of patients infected with hepatitis B.HBsAg quantification: useful for monitoring natural history and treatment outcome.HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility.Peginterferon α in the treatment of chronic hepatitis B.Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China.Chronic hepatitis B virus in young adults: the need for new approaches to management.Re-appraisal of old and new diagnostic tools in the current management of chronic hepatitis B.Update on hepatitis B virus infection.HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients.Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?How to achieve immune control in chronic hepatitis B?Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance.Advances in therapeutics for chronic hepatitis B.Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.
P2860
Q26740161-84A9ACCA-502B-43AD-9708-D43640F2C745Q26752475-B71955E4-1C34-4AE9-8817-DEBD83202EBDQ26771253-DFBF754C-5B08-456F-A39C-77ED66CA0299Q28067419-3EF6F959-454F-4B9E-B0DE-94F43851BBECQ30391932-DA9DA153-0CF7-4A79-8B07-5D53059B8BCDQ30487002-1AD16BF7-3403-40D0-976F-D9C8885D67C9Q33660010-79746240-C0A3-43C9-8020-E3AEDAD88F24Q33845546-5DD4EBD5-79C3-48B8-9A29-00390D9399F5Q33918392-692F2A5A-D5AD-4268-A503-3252E14399C7Q34785877-51D8EB73-774E-4082-8667-719BC83D8F23Q35118955-8249A9DF-5097-4CED-9AE9-8D2FC961BC19Q35663838-5830772D-E087-48FD-9465-B7409BC38D67Q35688409-5630228D-0256-4425-8368-4E30A2A83137Q35746110-B9AE907D-78DF-4DE4-9562-C82B98BA451DQ35866293-89439009-08B9-4FB1-9AF8-065582D69224Q36014403-09CA502A-A9C3-4FFB-9E2E-2A172A4DDB4BQ36307834-3ABBC3E3-A622-4B96-BE03-DD4463B3E5EBQ36898390-B91E06AA-1153-4170-89F6-F6DEB23A6829Q36924978-441FFD91-F243-410B-8814-C93B6006041EQ36958940-89468E74-A969-4916-BBE9-65396D88C6D2Q37087279-5A579EE8-6623-4776-A0EC-834D8E4B7421Q37165176-26D86616-5A35-4DCF-9560-331E7021204DQ37206545-2DFF5303-B62D-4804-9F57-5095750AA8D6Q37482902-4D0194F2-AD1C-49DE-89C9-DA0664A0820CQ37684139-B5B2D54A-29EE-4DC9-8C89-0EF661CD1378Q38168105-D89C53F2-5900-4EAC-BB0B-685737C3BCFDQ38174257-2BF45475-8268-4ECE-81A6-C8FA12E3387BQ38174259-3D94D23E-9815-45A7-BE86-A38CA9F738F5Q38177851-F8374D4C-0B1D-4BA9-88A9-ACDC92A58AD4Q38205028-9FC870C9-3A31-402C-BFAF-FE4815683F52Q38210344-17F69F9E-3C5E-4FC0-9E64-2F3765856DCFQ38232829-B3A83D6C-90D3-4037-A173-53088F3BB6FDQ38237418-006BBFAF-03E8-4CA2-90D1-BDB7FD63F519Q38259535-6CCF66FF-7680-40B2-8F46-47E51C2891EFQ38295840-537AC236-3E9D-4353-9EDC-F83DE1B11F57Q38295850-BB016BFC-219C-4608-8391-7D7B1CD0EC4EQ38383489-0B727B80-D8E5-4FBB-AC44-186B3F8E4015Q38408847-0B2E061B-5B31-48C8-B64F-981D930E73AAQ38585657-11E1A6CD-472A-4589-88F3-E58176FA59C7Q38601876-813C39BA-70BB-40E2-A5E1-1757830E1426
P2860
Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Response-guided peginterferon ...... itis B surface antigen levels.
@en
Response-guided peginterferon ...... itis B surface antigen levels.
@nl
type
label
Response-guided peginterferon ...... itis B surface antigen levels.
@en
Response-guided peginterferon ...... itis B surface antigen levels.
@nl
prefLabel
Response-guided peginterferon ...... itis B surface antigen levels.
@en
Response-guided peginterferon ...... itis B surface antigen levels.
@nl
P2093
P2860
P50
P356
P1433
P1476
Response-guided peginterferon ...... itis B surface antigen levels.
@en
P2093
E Jenny Heathcote
Edward Gane
Harry L A Janssen
Henry L-Y Chan
Ji-Dong Jia
Milan J Sonneveld
Teerha Piratvisuth
P2860
P304
P356
10.1002/HEP.26436
P407
P577
2013-07-29T00:00:00Z